Cargando…

Applying precision medicine to the active surveillance of prostate cancer

The recent introduction of a variety of molecular tests will potentially reshape the care of patients with prostate cancer. These tests may make more accurate management decisions possible for those patients who have been “overdiagnosed” with biologically indolent disease, which represents an except...

Descripción completa

Detalles Bibliográficos
Autores principales: Reichard, Chad A., Stephenson, Andrew J., Klein, Eric A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758404/
https://www.ncbi.nlm.nih.gov/pubmed/26149066
http://dx.doi.org/10.1002/cncr.29496
_version_ 1782416603174928384
author Reichard, Chad A.
Stephenson, Andrew J.
Klein, Eric A.
author_facet Reichard, Chad A.
Stephenson, Andrew J.
Klein, Eric A.
author_sort Reichard, Chad A.
collection PubMed
description The recent introduction of a variety of molecular tests will potentially reshape the care of patients with prostate cancer. These tests may make more accurate management decisions possible for those patients who have been “overdiagnosed” with biologically indolent disease, which represents an exceptionally small mortality risk. There is a wide range of possible applications of these tests to different clinical scenarios in patient populations managed with active surveillance. Cancer 2015;121:3435–43. © 2015 American Cancer Society.
format Online
Article
Text
id pubmed-4758404
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-47584042016-02-29 Applying precision medicine to the active surveillance of prostate cancer Reichard, Chad A. Stephenson, Andrew J. Klein, Eric A. Cancer Review Articles The recent introduction of a variety of molecular tests will potentially reshape the care of patients with prostate cancer. These tests may make more accurate management decisions possible for those patients who have been “overdiagnosed” with biologically indolent disease, which represents an exceptionally small mortality risk. There is a wide range of possible applications of these tests to different clinical scenarios in patient populations managed with active surveillance. Cancer 2015;121:3435–43. © 2015 American Cancer Society. John Wiley and Sons Inc. 2015-07-06 2015-10-01 /pmc/articles/PMC4758404/ /pubmed/26149066 http://dx.doi.org/10.1002/cncr.29496 Text en © 2015 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Reichard, Chad A.
Stephenson, Andrew J.
Klein, Eric A.
Applying precision medicine to the active surveillance of prostate cancer
title Applying precision medicine to the active surveillance of prostate cancer
title_full Applying precision medicine to the active surveillance of prostate cancer
title_fullStr Applying precision medicine to the active surveillance of prostate cancer
title_full_unstemmed Applying precision medicine to the active surveillance of prostate cancer
title_short Applying precision medicine to the active surveillance of prostate cancer
title_sort applying precision medicine to the active surveillance of prostate cancer
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758404/
https://www.ncbi.nlm.nih.gov/pubmed/26149066
http://dx.doi.org/10.1002/cncr.29496
work_keys_str_mv AT reichardchada applyingprecisionmedicinetotheactivesurveillanceofprostatecancer
AT stephensonandrewj applyingprecisionmedicinetotheactivesurveillanceofprostatecancer
AT kleinerica applyingprecisionmedicinetotheactivesurveillanceofprostatecancer